Literature DB >> 18405174

Vasculopathy and vasculitis in systemic lupus erythematosus.

Paweł Cieślik1, Antoni Hrycek, Piotr Kłuciński.   

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disease, where vascular lesions are one of the typical symptoms. The pathological process often involves skin vessels, renal glomeruli, the cardiovascular system, brain, lung alveoli, and gastrointestinal tract vessels. This review presents possible adverse mechanisms underlying the cause and effect relationship of various factors causing vascular lesions in SLE patients. The generally accepted hypothesis links vascular damage in SLE with the deposition of immune complexes in the vascular endothelium. The anti-endothelial cell antibodies (AECA), antiphospholipid antibodies and anti-double stranded DNA antibodies present in SLE, that directly or indirectly affect endothelial cells, causing inflammatory damage to the vessel wall, and their role, have been discussed. It has been stressed that although the suggested role of AECA in vasculitis pathogenesis has not been fully established, evidence, however, has demonstrated that AECA is a factor causing endothelial damage in SLE patients. On the other hand, issues concerning cellular adhesion molecules which enable leukocyte adhesion and rolling along the endothelial cell surface, and their extravascular migration, focus on the role they may be playing in SLE patients with vasculitis. A potential role of soluble forms of adhesion molecules, pentraxin 3, medications, infections in the pathogenesis of this disease has also been shown. Special attention has been given to the role of type 3 hepatitis virus in vascular damage in SLE.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18405174

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


  14 in total

Review 1.  Vasculitis in systemic lupus erythematosus.

Authors:  L Barile-Fabris; M F Hernández-Cabrera; J A Barragan-Garfias
Journal:  Curr Rheumatol Rep       Date:  2014       Impact factor: 4.592

Review 2.  Integrative neuroscience approach to neuropsychiatric lupus.

Authors:  Patricio T Huerta; Elizabeth L Gibson; Carson Rey; Tomás S Huerta
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

3.  A sequence of pathologic events in a patient after thymectomy for myasthenia gravis.

Authors:  Antoni Hrycek
Journal:  Rheumatol Int       Date:  2009-12-18       Impact factor: 2.631

Review 4.  Thrombosis and Anticoagulation Therapy in Systemic Lupus Erythematosus.

Authors:  Wenjun Yuan; Fengjun Guan
Journal:  Autoimmune Dis       Date:  2022-06-27

Review 5.  Connective Tissue Disorder-Associated Vasculitis.

Authors:  Aman Sharma; Aadhaar Dhooria; Ashish Aggarwal; Manish Rathi; Vinod Chandran
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

Review 6.  Chance, genetics, and the heterogeneity of disease and pathogenesis in systemic lupus erythematosus.

Authors:  Tony N Marion; Arnold E Postlethwaite
Journal:  Semin Immunopathol       Date:  2014-08-08       Impact factor: 9.623

Review 7.  A mouse model of the Δ133p53 isoform: roles in cancer progression and inflammation.

Authors:  Marina Kazantseva; Sunali Mehta; Ramona A Eiholzer; Noelyn Hung; Anna Wiles; Tania L Slatter; Antony W Braithwaite
Journal:  Mamm Genome       Date:  2018-07-10       Impact factor: 2.957

8.  Vascular disease in systemic lupus erythematosus.

Authors:  Athina Pyrpasopoulou; Sofia Chatzimichailidou; Spyros Aslanidis
Journal:  Autoimmune Dis       Date:  2012-08-22

9.  Serum levels of three angiogenic factors in systemic lupus erythematosus and their clinical significance.

Authors:  Ling Zhou; Guoyuan Lu; Lei Shen; Linfeng Wang; Mingjun Wang
Journal:  Biomed Res Int       Date:  2014-01-06       Impact factor: 3.411

Review 10.  Endothelial dysfunction in chronic inflammatory diseases.

Authors:  Curtis M Steyers; Francis J Miller
Journal:  Int J Mol Sci       Date:  2014-06-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.